help button home button The Oncologist http://theoncologist.alphamedpress.org/misc/eLetters.shtml
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
The Oncologist, Vol. 11, No. 1, 21-30, January 2006; doi:10.1634/theoncologist.11-1-21
© 2006 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow CME: Take the course for this article:
 Chronic Lymphocytic Leukemia: Recent Advances in Diagnosis and Treatment
Right arrow eLetters: Submit a response to this article
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Abbott, B. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Abbott, B. L.

Chronic Lymphocytic Leukemia: Recent Advances in Diagnosis and Treatment

Brian L. Abbott

Leukemia/Lymphoma Program, University of Colorado Health Science Center, Aurora, Colorado, USA

Key Words. CCL • Chronic lymphocytic leukemia • Rituximab • ZAP70

Correspondence: Brian L. Abbott, M.D., Leukemia/Lymphoma Program, University of Colorado Health Science Center, 1665 N. Ursula Street, Room CP-2254, (P.O. Box 6510 Mail Stop F-704), Aurora, Colorado 80010, USA. Telephone: 720-848-0300; Fax: 720-848-0360; e-mail: Brian.Abbott{at}uchsc.edu

Chronic lymphocytic leukemia (CLL) is a low-grade B-lineage lymphoid malignancy but may have more heterogeneity than previously thought. Many cases require no treatment at all because of an indolent course, while other patients become symptomatic or develop signs of rapid progression. Treatment is usually noncurative and is directed at reducing the symptoms. Some molecular risk features may help delineate, at initial diagnosis, which patients will have a more aggressive course. Newer CLL treatment regimens incorporating purine nucleoside analogues and monoclonal antibodies have increased the rate of molecular complete remissions, which may lead to better survival times. Reduced intensity allogeneic transplant conditioning regimens have made the potentially curative modality more widely available. All these treatments have significant risks for infectious complications, which must be carefully weighed against the risks posed by the underlying disease. A proposed risk-based treatment algorithm is discussed.




This article has been cited by other articles:


Home page
 J. Virol.Home page
V. F. Tumilasci, S. Oliere, T. L.-A. Nguyen, A. Shamy, J. Bell, and J. Hiscott
Targeting the Apoptotic Pathway with BCL-2 Inhibitors Sensitizes Primary Chronic Lymphocytic Leukemia Cells to Vesicular Stomatitis Virus-Induced Oncolysis
J. Virol., September 1, 2008; 82(17): 8487 - 8499.
[Abstract] [Full Text] [PDF]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS
http://theoncologist.alphamedpress.org/subscriptions/etoc.dtl

Copyright © 2006 by AlphaMed Press.